Ceva's pre-tax profits for 2010 came in at €23.5 million (US$33.8 million), up 66.1% over 2009, according to the company's latest report.
The company's sales grew in multiple product segments, according to the report. Anti-infective product sales rose by 11.7% with an increase of 12% in the Europe Zone and 11.3% for the International Zone. Like 2009, sales of biological products pursued their progression with growth of 27.9% overall, including 29% for poultry vaccines and 23.9% for large animal vaccines. Sales of companion animal products surged strongly (29.4%), mainly due to the integration of two newly acquired companies, with sales growing by 12% on a pro forma basis. Sales of antiparasitics were up sharply (28.9%) with growth standing at 16.9% on a constant consolidation scope.